Pegvisomant shown to provide more GH, IGF-1 suppression compared to octreotide. The doses used were 40, 60, and 80 mg SQ. The higher dose resulted in the greatest suppression.
epidemiological studies are the only thing that has linked GH to cancer risk; review of human studies of children and adults finds no increase risk of cancer associated with HGH therapy.
These data also suggest that endogenous progesterone could play a modulation role on pituitary hormone secretion, stimulating GH and PRL release and enhancing the inhibitory action of sleep on TSH secretion.
normally cycling young women, daytime GH and PRL secretions are increased in luteal phase
Thought GH in those with Prader-Willi Syndrome did not see an improvement in lipid and glucose metabolism, lean body mass increased and fat mass decreased.
Only abstract available here: compound resistance treaining in highly trained young men found to increase GH and Testosterone over isolation exercises. Those that trained > 2 years had significnt increase in Testosterone pre/post exercise compared to no statistical change in those traing < 2 years.
testosterone and Estradiol effect IGF-1 levels. This small study looked at 8 men and 8 postmenopausal women. Findings: low testosterone and high estradiol decrease IGF-1 availability. Estradiol in postmenopausal women will result in a decrease in IGF-1 through an elevation of IGFBP-1. In men, testosterone replacement stimulates increased HGH secretion and resultant IGF-1 secretion
Ghrelin, a peptide produced in the stomach and hypothalamus, stimulates
feeding and GH secretion
Centrally administered ghrelin exerts an orexigenic activity through the neuropeptide Y (NPY)
though ghrelin is predominantly produced in endocrine cells of the stomach (17, 18), it is also synthesized in the hypothalamic arcuate nucleus (1, 19), a critical region for feeding
oral estrogen therapy decreased IGF-1 concentrations in those women taking growth hormone, requiring high dosing of HGH versus that in women using estrogen through a transdermal approach.
IN men with low Testosterone, Testosterone therapy improved trabecular bone, but not cortical bone. Growth hormone provided no additional benefit. This study looked at men with panhypopituitarism.